Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025 Company to host conference ca ...

FORT COLLINS, Colo., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ:WWD), a global leader in energy control solutions for aerospace and industrial applications, announced today that it has entered a five-year Maintenance, Repair, and Overhaul (MRO) Services agreement with Lufthansa Technik. Lufthansa Technik is a provider of regular maintenance and repair of critical fuel system components operating within fleets of various commercial airlines. Woodward will continue to provide MRO work for Luftha ...

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA. The live and archived webcast can be accessed under "Events & Pres ...

PARSIPPANY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (NASDAQ:LINC) today announced financial and operating results for the second quarter ended June 30, 2024, as well as recent business developments. Second Quarter 2024 Financial Highlights* Revenue grew 16.1% to $102.9 millionStudent starts increased 12.3%; 11.4% increase in quarter-end student populationNet loss of $700,000 and Adjusted EBITDA of $6.2 millionTotal liquidity of more than $100 million; no debt outstan ...

Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increaseVOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults – unlocking the entire GERD market of over 22 million diagnose ...

Second Quarter Highlights – 2024 vs. 2023 Verification and certification revenue up 10% to $5.3 million from $4.8 millionProduct sales decline 13% to $0.8 million from $0.9 millionTotal revenue up 4% to $6.4 million from $6.1 millionNet income down 8% to $489,000 from $532,000Diluted EPS flat at $0.09Adjusted EBITDA of $844,000 vs. $917,000Company buys back 33,347 shares of stock in second quarter Six Month Highlights – 2024 vs. 2023 Verification and certification revenue up 13% to $9.7 million from $8.6 mi ...

Lowe's Media Network Unlocks More Opportunities that Deliver Growth for Brand PartnersMOORESVILLE, N.C., Aug. 8, 2024 /PRNewswire/ -- Lowe's Companies, Inc. is making new advancements to its media network to deliver a world-class retail media experience with enhanced white glove service for its brand advertisers. To support its strategic growth, Lowe's has rebranded its retail media network with a new logo and a simplified name: Lowe's Media Network. Lowe's also announced expanded placements on the Lowe's a ...

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"  Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Lumeon Limited ("Lumeon"), a digital health company with operations in the U.S. and United Kingdom dedicated to helping provider organizations mend broken care coordination processes through automated care orchestration. Leading providers in the U.S. ...

文章核心观点 - 公司将Recursion的生物探索和转化能力与Exscientia的精准化学设计和小分子自动合成能力结合,创建了一个领先的技术驱动的端到端药物发现平台 [1][2] - 结合后的公司将利用生命科学和技术的最新进展,为患者提供更好、更快、更低成本的新型治疗方法 [1][3][4] - 公司拥有丰富的临床管线,未来18个月内预计有约10个临床试验结果 [1][5] - 公司与多家大型制药公司建立了行业领先的合作伙伴关系,未来24个月内可能获得约2亿美元里程碑付款,整个合作期内可能获得超过200亿美元收益(不含版税) [1][6][12] - 公司资产负债表健康,截至2024年第二季度末拥有约8.5亿美元的现金及等价物 [1] - 预计整合后每年可产生超过1亿美元的协同效应 [1][14] 根据目录分别总结 管线 - 结合后的公司拥有多个临床和临床前项目,未来18个月内预计有约10个临床试验结果 [1][5][8] - 公司管线涵盖罕见病、精准肿瘤和传染病等领域,大部分成功项目有可能达到超过10亿美元的年峰值销售 [11] - 两家公司的管线互补,Recursion专注于首创药物,Exscientia专注于最佳在类药物 [11] - 两家公司还有多个研发和发现阶段的管线项目,将从两个平台的互补性中获益 [11] 合作伙伴 - 结合后的公司将拥有与多家大型制药公司(如罗氏-基因泰克、赛诺菲、拜耳和默克)的变革性合作关系,涉及10个肿瘤和免疫学领域的项目 [6][10][12] - 未来24个月内可能获得约2亿美元里程碑付款,整个合作期内可能获得超过200亿美元收益(不含版税) [1][6][12] 技术平台 - 结合后的公司将拥有一个全栈的技术驱动平台,涵盖从患者导向的靶标发现到临床开发的各个环节 [13] - Exscientia的自动化合成能力将使Recursion能够更快更有效地进行命中化合物到先导化合物的优化 [13] - 这些能力将产生多样性化学,有助于实验性地改善生物化学的预测模型 [13]

Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys Demonstrated favourable safety, consistent with established profile Companies plan to submit data for regulatory approval in the US and EU STOCKHOLM, Aug. 8, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pha ...